drugset
drugset / Trial / NCT05857566

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

NCT05857566 ↗

Phase 1 Completed 24 enrolled Response Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.

Timeline

Start
2023-05-16
Primary completion
2023-07-13
Completion
2023-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject RDX-002 Unknown 200 mg Oral

Indications

No indication recorded.